NASDAQ:LMNXLuminex Stock Price, Forecast & News

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LMNX shares have increased by 29.4% and is now trading at $35.08. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Luminex.

Luminex is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Luminex.

Luminex Co. (NASDAQ:LMNX) released its quarterly earnings results on Monday, May, 4th. The medical instruments supplier reported $0.01 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.02. The medical instruments supplier had revenue of $90.40 million for the quarter, compared to analysts' expectations of $82.30 million. Luminex had a negative net margin of 1.81% and a negative return on equity of 1.25%. Luminex's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.07 earnings per share. View Luminex's earnings history.

Luminex announced a quarterly dividend on Tuesday, May 26th. Investors of record on Thursday, June 18th will be given a dividend of $0.09 per share on Thursday, July 9th. This represents a $0.36 annualized dividend and a dividend yield of 1.03%. The ex-dividend date is Wednesday, June 17th. View Luminex's dividend history.

Luminex issued an update on its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $109-110 million, compared to the consensus revenue estimate of $106.25 million.

2 equities research analysts have issued 12 month target prices for Luminex's shares. Their forecasts range from $21.00 to $32.00. On average, they anticipate Luminex's share price to reach $26.50 in the next twelve months. This suggests that the stock has a possible downside of 24.5%. View analysts' price targets for Luminex.

Press coverage about LMNX stock has been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Luminex earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news about Luminex.

Luminex saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 5,560,000 shares, an increase of 39.0% from the June 15th total of 4,000,000 shares. Based on an average daily volume of 753,600 shares, the days-to-cover ratio is currently 7.4 days. Currently, 13.1% of the shares of the company are short sold. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), Verizon Communications (VZ), AbbVie (ABBV), American Express (AXP) and Micron Technology (MU).

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.23%), Bridge City Capital LLC (0.15%) and Exchange Traded Concepts LLC (0.03%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild and Randall Myers. View institutional ownership trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Bridge City Capital LLC. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, and Randall Myers. View insider buying and selling activity for Luminex.

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Exchange Traded Concepts LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir. View insider buying and selling activity for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $35.08.

Luminex has a market capitalization of $1.61 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

The official website for Luminex is www.luminexcorp.com.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]